Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Hepatocellular Carcinoma confined to the liver that is unresectable with surgery or unable to be treated with radiofrequency ablation diagnosed by biopsy or imaging criteria (CT/MRI)~* No segmental, lobar, or main portal vein thrombosis as evidenced by CT or MRI imaging~Inclusion Criteria~* Adults \> 18 years old of either gender~* Diagnosis of liver confined HCC confirmed by histology or American Association for the Study of Liver Diseases (AASLD) guidelines \[59,60\] \[appendix A\].~* Lesions \< 1 cm in diameter have a low likelihood of being malignant and should be followed. Lack of growth over 1-2 years suggests it is not HCC.~* AFP \>200 and radiological evidence (arterial hypervascularity) of lesion \> 2 cm does not require biopsy.~* Two imaging modalities (triphasic CT, MRI, ultrasound, angiography) demonstrating arterial hypervascularity in the background of cirrhosis does not require biopsy~* One imaging modality with a lesion with arterial hypervascularity with wash out in early or delayed venous phase, does not require a biopsy~* Atypical appearances on imaging requires a biopsy.~* Non-conclusive biopsy requires closer monitoring~* For non-cirrhotics (by biopsy or imaging findings), diagnosis of HCC requires biopsy~* Patients with \<50% liver involvement~* Measurable liver confined disease with bi-dimensional measurements, required within 4 weeks of screening. Lesions reported on imaging as too small to characterize, abdominal lymph nodes \< 2.0 cm or ascites in the setting of cirrhosis are not considered metastatic disease unless cytology proven.~* No segmental, lobar or main portal vein thrombosis as evidence by cross sectional imaging~* Prior resection permitted, no prior systemic, ablative or infusion therapy permitted~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 \[appendix B\]~* Childs score of A or B \[appendix C\]~* Required lab parameters within 28 days of screening~* Serum bilirubin ≤ 2.0 mg/dl (unless segmental infusion can be performed~* AST and ALT ≤ 5 times upper limit of normal (ULN)~* Creatinine ≤ 1.5 times ULN~* Prothrombin time (PT)/ International normalized ratio (INR) ≤ 2.3 or PT ≤ 6 seconds above control. If subjects are being anticoagulated they can participate if proof of no coagulation abnormality existed prior to use of anticoagulants~* Negative serum or urine pregnancy test for females of child bearing potential~* Ability to understand and sign the informed consent; patient must have signed informed consent prior to registration on study~* Women of childbearing potential and sexually active males must use contraception while on study~* Lesions must be treatable angiographically by either radioembolization or chemoembolization.~Exclusion criteria~* Cardiac disease: Congestive heart failure \> class II New York Heart Association (NYHA). Patients must not have unstable angina (angina symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.~* Patients with infiltrative HCC are not eligible.~* Patients with bulk disease (≥70% tumor replacement of liver) are not eligible.~* Patients with ≥50% tumor replacement of liver, with an albumin \< 3.0 g/dl are not eligible.~* Major surgery within 4 weeks prior to the screening visit~* Active clinically serious infection \> Common Toxicity Criteria for Adverse Events (CTCAE v 4.0) Grade 2~* Any condition (psychological, physical or use/abuse of substances) which, in the opinion of the principal investigator (PI) or a sub-investigator (sub-I), would possibly endanger the subject during their participation in the study, or allow for non-compliance with the investigational drug and treatment under study.~* Due to the experimental nature of the therapy and the unknown risk to a fetus, pregnant and/or lactating women are not eligible to participate in this study.~* In the opinion of the investigator, patient is not a candidate/lesion not amenable for RFA (e.g. lesion location, shape, abnormal coagulation parameters, multi-focality).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (radioembolization) (Type: EXPERIMENTAL): Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
- Arm II (transarterial chemoembolization [TACE]) (Type: EXPERIMENTAL): Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).